黑色素瘤相关抗原A基因在乳腺癌中的表达及其临床意义

doi:10.3969/j.issn.1004-616x.2022.03.004

Abstract

Abstract: OBJECTIVE: To investigate expressions of melanoma-associated antigen A family (MAGE-As)in peripheral blood and cancer tissues from breast cancer patients,and to analyze their relationships with clinical parameters. METHODS: Expression levels of MAGE-As mRNA in peripheral blood of 106 breast cancer patients and 30 healthy controls were detected by multi-nested PCR,and expression levels of MAGE-A1,A2,A3,A4 and A6 were identified by restriction endonuclease digestion method.Expressions of MAGE-As protein in paraffin-embedded tissues of cancer tissues were detected by immunohistochemistry.Correlations between expressions of MAGE-As mRNA in peripheral blood and of MAGE-As protein in corresponding tumor tissues were analyzed. RESULTS: Positive expression rate of MAGE-As mRNA in the blood samples from patients was 40.5%(43/106).Expression rates of MAGE-A1,A2,A3,A4 and A6 were 10.3%(11/106),19.8%(21/106),15.1%(16/106),13.2%(14/106) and 5.7%(6/106),respectively.The sequence of MAGE-As gene expressions was A2>A3>A4>A1>A6.The MAGE-As mRNA expression was positively correlated with age,tumor size,clinical stage and lymph node metastasis (P<0.05).Expressions of MAGE-As mRNA in blood samples of patients were positively correlated with expression of MAGE-As protein in corresponding tumor tissues (r=0.368,P<0.01).Positive expressions of MAGE-As subtypes (MAGE-A1,A2,A3,A4 and A6)were correlated with 5-year survival rates of breast cancer patients (P<0.01).MAGE-As expression and lymph node metastasis were independent prognostic factors for 5-year survival of these patients (all P<0.01). CONCLUSION: MAGE-As may be a specific biomarker for detection of circulating tumor cells in peripheral blood of breast cancer patients,and its expression was correlated with the prognosis of these patients.MAGE-As in peripheral blood of breast cancer patients may be useful as an important biomarker to monitor prognosis of breast cancer.

Key words: breast cancer, MAGE-As, peripheral blood, multiplex semi-nested PCR

CLC Number:

R737.9

FAN Xiaojie, LI Qingjing, GU Lina, SANG Meixiang, SHAN Baoen. Expression of melanoma-associated antigen A gene family in breast cancer and its clinical significance[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(3): 184-191.

References

[1] SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
[2] LEI S Y, ZHENG R S, ZHANG S W, et al. Global patterns of breast cancer incidence and mortality:a population-based cancer registry data analysis from 2000 to 2020[J]. Cancer Commun(Lond), 2021, 41(11):1183-1194.
[3] SANG M X, WU X H, FAN X J, et al. MAGE-A family serves as poor prognostic markers and potential therapeutic targets for epithelial ovarian cancer patients:a retrospective clinical study[J]. Gynecol Endocrinol, 2017, 33(6):480-484.
[4] 谷丽娜,尹丹静,桑梅香,等.黑色素瘤相关抗原A基因家族在食管癌患者外周血中的表达及其临床意义[J].中国肿瘤生物治疗杂志, 2018, 25(8):803-809.
[5] TELLEZ-GABRIEL M, BROWN H K, YOUNG R, et al. The challenges of detecting circulating tumor cells in sarcoma[J].Front Oncol, 2016, 6:202.
[6] LIOTTA L A, SAIDEL M G, KLEINERMAN J. The significance of hematogenous tumor cell clumps in the metastatic process[J]. Cancer Res, 1976, 36(3):889-894.
[7] MAGBANUA M J M, RUGO H S, WOLF D M, et al. Expanded genomic profiling of circulating tumor cells in metastatic breast cancer patients to assess biomarker status and biology over time(CALGB 40502 and CALGB 40503, alliance)[J]. Clin Cancer Res, 2018, 24(6):1486-1499.
[8] STRATI A, NIKOLAOU M, GEORGOULIAS V, et al.Prognostic significance of TWIST1, CD24, CD44, and ALDH1transcript quantification in EpCAM-positive circulating tumor cells from early stage breast cancer patients[J]. Cells, 2019, 8(7):652.
[9] CABEL L, BERGER F, COTTU P, et al. Clinical utility of circulating tumour cell-based monitoring of late-line chemotherapy for metastatic breast cancer:the randomised CirCe01 trial[J].Br J Cancer, 2021, 124(7):1207-1213.
[10] GOODMAN C R, SPEERS C W. The role of circulating tumor cells in breast cancer and implications for radiation treatment decisions[J]. Int J Radiat Oncol Biol Phys, 2021, 109(1):44-59.
[11] MILLNER L M, LINDER M W, VALDES R Jr. Circulating tumor cells:a review of present methods and the need to identify heterogeneous phenotypes[J]. Ann Clin Lab Sci, 2013,43(3):295-304.
[12] PRIETO-GARCÍA E, DÍAZ-GARCÍA C V, GARCÍA-RUIZ I,et al. Epithelial-to-mesenchymal transition in tumor progression[J]. Med Oncol, 2017, 34(7):122.
[13] NIETO M A, HUANG R Y J, JACKSON R A, et al. Emt:2016[J]. Cell, 2016, 166(1):21-45.
[14] WANG Y X, LI F L, DU L X, et al. The co-expression of melanoma-antigen family a proteins and New York esophageal squamous cell carcinoma-1 in breast cancer:a pilot study[J].Cancer Manag Res, 2021, 13:6123-6128.
[15] OH C, KIM H R, OH S, et al. Epigenetic upregulation of MAGE-A isoforms promotes breast cancer cell aggressiveness[J]. Cancers, 2021, 13(13):3176.
[16] WANG H, SANG M, GENG C, et al. MAGE-A is frequently expressed in triple negative breast cancer and associated with epithelial-mesenchymal transition[J]. Neoplasma, 2016, 63(1):44-56.
[17] GU L N, SANG M X, YIN D J, et al. MAGE-A gene expression in peripheral blood serves as a poor prognostic marker for patients with lung cancer[J]. Thorac Cancer, 2018, 9(4):431-438.
[18] OTTE M, ZAFRAKAS M, RIETHDORF L, et al. MAGE-A gene expression pattern in primary breast cancer[J]. Cancer Res, 2001, 61(18):6682-6687.
[19] HAMZA A, SAKHI R, ALRAJJAL A, et al. Tumor size in breast carcinoma:gross measurement is important![J]. Int J Surg Pathol, 2018, 26(6):494-499.
[20] TEICHGRAEBER D C, GUIRGUIS M S, WHITMAN G J.Breast cancer staging:updates in the AJCC cancer staging manual, 8th edition, and current challenges for radiologists,from the AJR special series on cancer staging[J]. AJR Am J Roentgenol, 2021, 217(2):278-290.

Expression of melanoma-associated antigen A gene family in breast cancer and its clinical significance

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	WANG Xujuan, LUO Yongxin, LI Chenqiang, WANG Rujin, ZHENG Tingting. Predictive values of preoperative laboratory indices dNLR, SII and CRP/ALB on recurrences and metastases in breast cancer patient [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(4): 284-288,323.
[2]	XIN Yumeng, LIANG Huanxi, SUN Zhenxiao. Effectiveness of licorice and dried ginger decoction against mouse breast cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(2): 88-92.
[3]	GUO Xiaojuan, WANG Jinxi, NIU Guangxu, TIAN Yunxiao. Expression and correlation analyses of EGFR and HER-2 in different types of breast cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(2): 119-123,148.
[4]	XIN Yumeng, LIANG Huanxi, YU Yuehua, SUN Zhenxiao. Network pharmacology and molecular docking mechanisms of licorice and dried ginger decoction against breast cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(1): 7-13.
[5]	ZHAO Yan, SUN Zhenxiao. Metformin inhibitd proliferation and migration of human breast cancer cell in vitro [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(1): 35-39.
[6]	FANG Yutong, ZHANG Qunchen, HONG Chaoqun, CHEN Chunfa, CHEN Jiongyu, ZHANG Rendong, WU Jundong. Mechanisms of miR-221 and miR-222 on expression of GATA3 and FOXA1 and their effects in breast cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(6): 435-441,460.
[7]	ZHANG Shimin, ZHAO Ruijun. Expression of protein tyrosine phosphatase receptor J in breast cancer tissues and its relationship with clinical prognosis [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 276-279,285.
[8]	CHENG Bin, WANG Xinyu, SUN Yu, ZHANG Jiatai, DONG Shuying. Inhibition of metformin on phthalate-induced proliferation and migration of MCF-7 breast cancer cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 197-202.
[9]	LUO Jiao, ZHANG Kunchi, ZHOU Li. Analysis of differentially expressed microRNAs between the triple negative breast cancer cell line MDA-MB-231 and its brain metastasis cell line [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 218-224.
[10]	LI Weiwei, ZHU Ying. Data mining analyses of expression and prognostic values of the MYB family in breast cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(6): 414-422.
[11]	CHEN Mianling, MA Shuoyi. Regulation of migration and invasion of triple-negative breast cancer cell MDA-MB-231 by miR-21 via targeting PDCD4 [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(4): 292-297.
[12]	ZHANG Huijuan, HUANG Dayuan, ZHANG Jie, TANG Haiou, XIE Anxin, TAN Dunyong. Effects of SF1a-PRLR and ΔS2 SF1a-PRLR on proliferation and microRNA expressionin MCF-7 breast cancer cell [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(3): 203-208.
[13]	SUN Quanwu, DU Xiaoping, HAO Jie, SHI Rong, LIU Bo, HUANG Haiyun. β1 integrin expression in breast cancer patients with pathological nipple discharge [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(5): 368-372.
[14]	WANG Lan, ZHANG Yongdong, GUO Hongyun, WANG Tao, WANG Haitao, GUO Huan, YANG Suisheng, LI Xiaoqin, SU Haixiang. Relationships between XRCC3 polymorphisms and breast cancer in northern Chinese women [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(5): 392-396,400.
[15]	DU Juan, HU Xiangyang, LIU Dan, HU Wei, CHEN Tao. Inhibitory effect of total alkaloids of Tougucao on bone metastasis of breast cancer cells in mice [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(6): 435-441.